WO2001012661A3 - RECEPTOR-MEDIATED UPTAKE OF AN EXTRACELLULAR BCL-xL FUSION PROTEIN INHIBITS APOPTOSIS - Google Patents

RECEPTOR-MEDIATED UPTAKE OF AN EXTRACELLULAR BCL-xL FUSION PROTEIN INHIBITS APOPTOSIS Download PDF

Info

Publication number
WO2001012661A3
WO2001012661A3 PCT/US2000/022293 US0022293W WO0112661A3 WO 2001012661 A3 WO2001012661 A3 WO 2001012661A3 US 0022293 W US0022293 W US 0022293W WO 0112661 A3 WO0112661 A3 WO 0112661A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
fusion protein
mediated uptake
protein inhibits
inhibits apoptosis
Prior art date
Application number
PCT/US2000/022293
Other languages
French (fr)
Other versions
WO2001012661A2 (en
Inventor
Richard J Youle
Xiuhuai Liu
R John Collier
Original Assignee
Us Health
Harvard College
Richard J Youle
Xiuhuai Liu
R John Collier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, Harvard College, Richard J Youle, Xiuhuai Liu, R John Collier filed Critical Us Health
Priority to AU69061/00A priority Critical patent/AU6906100A/en
Publication of WO2001012661A2 publication Critical patent/WO2001012661A2/en
Publication of WO2001012661A3 publication Critical patent/WO2001012661A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Apoptosis-modifying fusion polypeptides, and the corresponding nucleic acid molecules, are disclosed. Pharmaceutical compositions comprising these polypeptides, and the use of these polypeptides to modify apoptosis are also provided.
PCT/US2000/022293 1999-08-16 2000-08-15 RECEPTOR-MEDIATED UPTAKE OF AN EXTRACELLULAR BCL-xL FUSION PROTEIN INHIBITS APOPTOSIS WO2001012661A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU69061/00A AU6906100A (en) 1999-08-16 2000-08-15 Receptor-mediated uptake of an extracellular bcl-xl fusion protein inhibits apoptosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14922099P 1999-08-16 1999-08-16
US60/149,220 1999-08-16

Publications (2)

Publication Number Publication Date
WO2001012661A2 WO2001012661A2 (en) 2001-02-22
WO2001012661A3 true WO2001012661A3 (en) 2001-09-20

Family

ID=22529285

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/022293 WO2001012661A2 (en) 1999-08-16 2000-08-15 RECEPTOR-MEDIATED UPTAKE OF AN EXTRACELLULAR BCL-xL FUSION PROTEIN INHIBITS APOPTOSIS

Country Status (2)

Country Link
AU (1) AU6906100A (en)
WO (1) WO2001012661A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003267124A1 (en) * 2002-09-09 2004-03-29 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
CN101495509B (en) * 2005-07-08 2015-04-22 比奥根艾迪克Ma公司 SP35 antibodies and uses thereof
CA2622504A1 (en) * 2005-09-09 2008-03-08 Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for inhibiting cell death or enhancing cel proliferation
EP2008106A2 (en) 2006-03-31 2008-12-31 Dana-Farber Cancer Institute Methods of determining cellular chemosensitivity
FR2988393B1 (en) * 2012-03-20 2014-05-09 Commissariat Energie Atomique INHIBITOR OF DIPHTERIC TOXIN-DOMAIN R-DERIVED HB-EGF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH HB-EGF / EGFR ENHANCEMENT
WO2014047342A1 (en) 2012-09-19 2014-03-27 Dana-Farber Cancer Institute, Inc. Dynamic bh3 profiling
JP6663852B2 (en) 2013-09-19 2020-03-13 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド BH3 profiling method
CN107995863A (en) 2015-04-20 2018-05-04 特雷罗药物股份有限公司 Response of the prediction to Avobenzene west ground is analyzed by mitochondria
CA2983024A1 (en) 2015-04-27 2016-11-03 Dana-Farber Cancer Institute, Inc. Compositions and methods for assessing toxicity using dynamic bh3 profiling
AU2016264212B2 (en) 2015-05-18 2020-10-22 Sumitomo Pharma Oncology, Inc. Alvocidib prodrugs having increased bioavailability
WO2017024073A1 (en) 2015-08-03 2017-02-09 Tolero Pharmaceuticals, Inc. Combination therapies for treatment of cancer
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
WO2018119000A1 (en) 2016-12-19 2018-06-28 Tolero Pharmaceuticals, Inc. Profiling peptides and methods for sensitivity profiling
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. Treatment regimen for cancers that are insensitive to bcl-2 inhibitors using the mcl-1 inhibitor alvocidib
EP3890749A4 (en) 2018-12-04 2022-08-03 Sumitomo Dainippon Pharma Oncology, Inc. Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018332A2 (en) * 1993-02-12 1994-08-18 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Anthrax toxin fusion proteins and uses thereof
WO1997041227A1 (en) * 1996-05-01 1997-11-06 T Cell Sciences, Inc. Plasmid-based vaccine for treating atherosclerosis
WO1998017682A1 (en) * 1996-10-18 1998-04-30 Washington University Serine substituted mutants of bcl-xl/bcl-2 associated cell death regulator
WO1999045128A2 (en) * 1998-03-02 1999-09-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Chimeric proteins with cell-targeting specificity and apoptosis-dinducing activities

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018332A2 (en) * 1993-02-12 1994-08-18 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Anthrax toxin fusion proteins and uses thereof
WO1997041227A1 (en) * 1996-05-01 1997-11-06 T Cell Sciences, Inc. Plasmid-based vaccine for treating atherosclerosis
WO1998017682A1 (en) * 1996-10-18 1998-04-30 Washington University Serine substituted mutants of bcl-xl/bcl-2 associated cell death regulator
WO1999045128A2 (en) * 1998-03-02 1999-09-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Chimeric proteins with cell-targeting specificity and apoptosis-dinducing activities

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOISE L H ET AL: "BCL-X, A BCL-2-RELATED GENE THAT FUNCTIONS AS A DOMINANT REGULATOR OF APOPTOTIC CELL DEATH", CELL, vol. 74, 27 August 1993 (1993-08-27), pages 597 - 608, XP002018919, ISSN: 0092-8674 *
LIU X.-H. ET AL.: "Receptor-mediated uptake of an extracellular Bcl-x(l) fusion protein inhibits apoptosis", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, USA, vol. 96, no. 17, 17 August 1999 (1999-08-17), pages 9563 - 9567, XP002159673 *
NEWTON K. ET AL.: "The Bcl-2 family and cell death regulation", CURRENT OPINION IN GENETICS & DEVELOPMENT, vol. 8, no. 1, February 1998 (1998-02-01), pages 68 - 75, XP000926158 *

Also Published As

Publication number Publication date
WO2001012661A2 (en) 2001-02-22
AU6906100A (en) 2001-03-13

Similar Documents

Publication Publication Date Title
WO2001012661A3 (en) RECEPTOR-MEDIATED UPTAKE OF AN EXTRACELLULAR BCL-xL FUSION PROTEIN INHIBITS APOPTOSIS
AU2003246810A1 (en) Diphenylpyridine derivatives, the preparation thereof, and pharmaceutical compositions containing said derivatives
DK1024786T3 (en) Skin friendly hand cleansers, especially coarse hand cleansers
WO2003011115A3 (en) Peptide-based multimeric targeted contrast agents
AU1392199A (en) Low-ph, acid-containing personal care compositions which exhibit reduced sting
HUP0200312A3 (en) Substituted 2-phenylbenzimidazoles, pharmaceutical compositions containing them, the production thereof and their use
AU4498500A (en) Phytyl/prenyltransferase nucleic acids, polypeptides and uses thereof
WO2004058837A3 (en) Ampholytic copolymer and use thereof
ZA200106408B (en) Cosmetic composition.
FR2811552B1 (en) COMPOSITION, IN PARTICULAR COSMETIC OR PHARMACEUTICAL, IN SOLID FORM
HK1027957A1 (en) Pharmaceutical composition.
AU2002232819A1 (en) Methods for the production of multimeric proteins, and related compositions
DE69937573D1 (en) EXTRACELLULAR, NEW RAGE-BINDING PROTEIN (EN-RAGE) AND ITS USES
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
WO2004046365A3 (en) Interferon-alpha polypeptides and conjugates
FR2791059B1 (en) MODIFIED PROTEIN, PROCESS FOR PREPARING THE SAME, AND COMPOSITIONS FOR EXTERNAL APPLICATION CONTAINING THE MODIFIED PROTEIN
DE59800439D1 (en) Crosslinkable powder composition redispersible in water
ZA989680B (en) Pharmaceutical composition.
AU2003234198A1 (en) Novel genes, compositions, and methods for modulating the unfolded protein response
HK1029928A1 (en) Pharmaceutical compositions of peptides having lowsolubility in physiological medium.
HK1022853A1 (en) Pharmaceutical compositions.
AU2003219046A1 (en) Cationic polymers and the use thereof in cosmetic formulations
WO2001064837A8 (en) β NETRIN AND USES THEREOF
ZA987392B (en) Pharmaceutical composition.
ZA200203078B (en) Ciclesonide-containing aqueous pharmaceutical composition.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP